129SVJ lambda FIX II genomic library (Stratagene, La Jolla, California, USA), as described previously (21) , and a 16-kb segment of DNA (λmATG1) containing the antithrombin initiation codon to the sixth intron was obtained. The sequence data have been deposited in DNA Data Bank of Japan (DDBJ)/European Molecular Biology Laboratory (EMBL)/GenBank (accession number AB043785). The detailed features of the gene structure and its comparison with the human antithrombin gene will be discussed elsewhere.
Construction of a targeting vector for homologous recombination in embryonic stem cells. The targeting vector was constructed from a basic vector with MC1neo (polyoma virus thymidine kinase gene promoter and neomycin resistance gene) and DTA (diphtheria toxin fragment A gene) (22) and antithrombin gene fragments. We used a 2.1-kb SspI/PvuII fragment as the 5′ arm and a 7.3-kb HindIII/SmaI fragment as the 3′ arm to replace 1,781 bases, including exon 2 of the antithrombin gene with MC1neo by homologous recombination (Figure 1a ). The generation of targeted D3 embryonic stem (ES) cells and blastocyst injection were performed as described previously (9, 23) .
Generation of antithrombin-deficient mice. Male chimeric mice were mated with C57BL/6J female mice, and F 1 mice heterozygous for antithrombin gene (ATIII) disruption, ATIII +/-, were mated with each other to yield null mutant mice. Noon on the day of vaginal plug detection was defined as 0.5 gestational days (gd). Females were sacrificed and the embryos harvested at various times during gestation. We defined embryonic death by the absence of a heartbeat at first inspection. The lower limbs and tail of the embryos were used for Southern blot and PCR analyses. The remaining embryos were used for RT-PCR, Western blot, or histological analyses. For histological analysis, the embryos were fixed overnight in Carnoy's solution (methanol/chloroform/acetic acid = 6:3:1). The fixed embryos were then dehydrated, embedded in paraffin, and sectioned (6 µm thick).
Preparation of anti-mouse antithrombin antisera. The antisera against mouse antithrombin were raised in rabbits by direct introduction of the encoding cDNA in pCI vector (Promega, Madison, Wisconsin, USA) (24) . From the antisera, nonspecific Ab's were absorbed with dry powder derived from ATIII -/-embryos at 14.5 gd. Serum titers were determined by Western blot analysis using recombinant mouse antithrombin fused to glutathione-S-transferase protein (Amersham Pharmacia Biotech, Tokyo, Japan) and rat antithrombin (SigmaAldrich, St. Louis, Missouri, USA).
Detection of antithrombin-deficient mice
DNA analysis. PCR was performed with a forward primer (5′-CCTTCCAGACCGAACTGTCC) and a reverse primer (5′-GTAATCCCAGCCTTCTCCTG) to detect the expected deletion (Figure 1a) . The PCR conditions were 35 cycles of denaturation for 30 seconds at 94°C, annealing for 1 minute at 68°C, and extension for 3 minutes at 72°C. The wild-type allele gave a 2.0 kb band, whereas the mutant allele gave a 1.3-kb band (Figure 1b) .
We also performed Southern blot analysis. After digestion with PvuII and hybridization with an external probe (a 658-base HindIII/SspI fragment; Figure 1a) , the wild-type allele gave a 4.4-kb band, whereas the mutant allele gave a 5-kb band (Figure 1c) .
RNA analysis. Total RNA was isolated from the single embryo of each genotype at 14.5 gd by the guanidinium thiocyanate-phenol-chloroform method (25) . RT-PCR was performed with primers mAT3S and mAT3AS, described above, yielding a 355-bp fragment. The PCR conditions were 25 cycles of denaturation for 30 seconds at 94°C, annealing for 1 minute at 55°C, and extension for 1 minute at 72°C.
Protein analysis. The whole liver of a single ATIII +/+ or ATIII -/-embryo at 14.5 gd was homogenized in PBS (500 µl). After centrifugation, the supernatant was rotated with protein G-Sepharose (40 µl of 50% slurry) (Amersham Pharmacia Biotech) for 1 hour at 4°C. After centrifugation, the supernatant was rotated with goat anti-human antithrombin Ab (8 µg) (Cedarlane Laboratories, Hornby, Ontario, Canada) and protein GSepharose (40 µl of 50% slurry) for 1 hour. The bound antithrombin was isolated together with IgG protein-G-Sepharose complex by centrifugation, washed with PBS, and eluted by incubation at 100°C for 5 minutes with 4% SDS (30 µl). Samples were applied to 8% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane for blotting with rabbit anti-mouse antithrombin antisera (1:10 dilution). Anti-rabbit IgG Ab conjugated with horseradish peroxidase was used for detection. The samples were visualized with enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech).
Measurement of plasma antithrombin. The levels of antithrombin antigen and activity in plasma were determined using N-assay TIA AT-III, which is a turbidimetric immunoassay for antigen-Ab complex, and N-test ATIII-S, which determines its enzymatic activity using a chromogenic substrate (Nittohbo, Tokyo, Japan), according to the manufacturer's instructions.
Statistical analysis. Stat View 4.5 (SAS Institute Inc., Cary, North Carolina, USA) was used for statistical analyses. P values were calculated with Student's t test.
Antifibrin(ogen) immunohistochemical staining. Slides were deparaffinized in xylene, transferred to 100% ethanol, and then incubated for 30 minutes in 0.3% H 2 O 2 /methanol. After rinsing with PBS, the slides were incubated successively with 5% normal goat serum/PBS (20 minutes, room temperature), rabbit anti-mouse fibrin(ogen) Ab (26) (1:200 dilution, overnight, 4°C), anti-rabbit IgG Ab conjugated with biotin (1:500 dilution, 1 hour, room temperature), and avidin-biotin complex conjugated with horseradish peroxidase (Vector Laboratories, Burlingame, California, USA) (30 minutes, room temperature). The staining was visualized with diaminobenzidine tetrahydrochloride-Ni 3+ , Co 2+ (Amersham Pharmacia Biotech). 100% (eight of eight embryos) at 16.5 gd had died and showed extensive subcutaneous hemorrhage ( Figure  2 ). No ATIII -/-mice were observed among the 75 F 2 newborn mice (Table 1) . Thirteen dead ATII -/-embryos (five embryos at 15.5 gd and eight at 16.5 gd) were examined histologically. In all of them, fibrin(ogen) deposition was detected in the degenerated myocardium and liver ( Figure 3, c-f ). In the liver, fibrin(ogen) deposition was observed in the sinusoids, but not in the central veins (Figure 3f ). Even in all of five living ATIII -/-embryos at 15.5 gd and one of four living ATIII -/-embryos examined at 14.5 gd, the myocardium was partially degenerated where fibrin(ogen) deposition was detected (Figure 4 ). In three of five living ATIII -/-embryos at 15.5 gd, the liver was also partially degenerated where fibrin(ogen) was detected in the sinusoids (data not shown). These observations suggest that the degeneration of the myocardium and liver of dead ATIII -/-embryos is due to intravascular coagulation rather than the natural progression of the absorption of dead embryos. It seems likely that fibrin deposition among degenerating myocardial fibers is secondary, perhaps from hemorrhage into the necrotic tissue. In other tissues, including the brain, lung, and kidney, no fibrin(ogen) deposition was observed by immunohistochemical staining, even though there was apparent tissue degeneration. Extensive hemorrhage was observed subcutaneously and intracranially (Figure 5a ), but no apparent fibrin(ogen) deposition was detected by immunohistochemical staining (Figure 5b ), suggesting that fibrinogen in plasma may have been decreased by consumptive coagulopathy and/or liver dysfunction in the dead ATIII -/-embryos.
Discussion
It has been suggested that the contribution of a given anticoagulant mechanism to the hemostatic balance varies from one vascular bed to another, and thrombosis occurs in an organ-specific fashion through the critical interplay of genetic and environmental factors (27) . Whereas individuals with heterozygous antithrombin deficiency are susceptible to venous thromboembolic diseases (10-12), a homozygous variant of antithrombin that lacks affinity for heparin causes thrombosis not only in veins but also in arteries (15) (16) (17) . In this study, we demonstrated that complete antithrombin deficiency was lethal to embryos. The reason for embryonic death during mid-late embryogenesis appears to be fibrin deposition in the myocardium and liver, since antithrombin deficiency caused fibrin(ogen) deposition around 15.5 gd in the degenerated myocardium and liver, but apparently did not in other regions. Although a small amount of fibrin(ogen) deposition undetectable by immunohistochemical staining might be present in several other organs, the myocardium and liver seemed to be more susceptible than other tissues to fibrin(ogen) deposition in antithrombin deficiency. Previous reports have demonstrated that disruption of the tissue-factor pathway inhibitor (TFPI) or protein C (PC) gene also causes fibrin(ogen) deposition
876
The in the liver (18, 28) , although its location was not discussed in detail. In ATIII -/-embryos, fibrin(ogen) deposition was detected in the sinusoids of the liver, but not in the central veins. It has been reported that expression of thrombomodulin and TFPI is not detected in the sinusoids of the liver (29, 30) , suggesting that anticoagulation in the sinusoid of the liver might be dependent on antithrombin. In contrast, such disruption of the TFPI or PC gene does not cause severe fibrin(ogen) deposition in the embryonic myocardium (18, 28) ; this is peculiar to ATIII -/-embryos. Although the mechanism leading to the organ-specific fibrin(ogen) deposition in ATIII -/-embryos remains to be elucidated, these observations suggest that antithrombin may be an important anticoagulant protein in the myocardium and sinusoids of the liver during embryogenesis. Beyond 15.5 gd, dead ATIII -/-embryos had extensive hemorrhage, with no fibrin(ogen) deposition detectable by immunohistochemical staining, suggesting that fibrinogen may be decreased by consumptive coagulopathy and/or liver dysfunction. Mice with fibrinogen deficiency suffer hemorrhagic symptoms postnatally but are born in normal numbers (31) . On the other hand, embryos with TFPI (18) or antithrombin deficiency have a severe hemorrhagic phenotype. Severe hemorrhage of these anticoagulant-deficient embryos may be attributed to the combined defects of plasma and cellular hemostatic components with extensive intravascular coagulation.
The plasma levels of antithrombin antigen and activity were significantly reduced in ATIII +/-mice compared with ATIII +/+ mice. However, ATIII +/-mice appear to be indistinguishable from ATIII +/+ mice and did not experience any apparent thromboembolic events during observation through 4 months of age. Most subjects with heterozygous antithrombin deficiency are asymptomatic (32, 33) , although antithrombin deficiency is obviously a risk factor for thromboembolic diseases, especially deep venous thrombosis of the lower limb and pulmonary embolism (10) (11) (12) . The ATIII +/-mouse will be a useful animal model for studying the mechanism of thromboembolic events observed in human heterozygous antithrombin deficiency. 
Figure 5
Hematoxylin-eosin (a) and immunohistochemical staining with anti-fibrin(ogen) Ab (b) of the head of a dead ATIII -/-embryo at 16.5 gd. Extensive hemorrhage was observed subcutaneously and intracranially (a), but there was no apparent fibrin(ogen) deposition (b). Size bar, 100 µm.
